Biotechnology

Promising Phase 2 data for AP-101 shows it slows ALS progression by targeting a key toxic protein, offering new hope beyond purely genetic approaches.

A new collaboration brings a Swedish-engineered vein therapy to the U.S., offering hope to millions with CVI by replacing diseased tissue with a living graft.

The $2B market for chronic hives is exploding, with new drugs from Sanofi, Celldex, and Novartis creating a seismic shift for patients and investors.

LambdaVision and Vast are partnering to build artificial retinas in orbit, a key signal that the low-Earth orbit economy is ready for business.

A new RNA therapy for obesity is advancing in trials. It promises to reduce harmful visceral fat, preserve muscle, and may only require a twice-yearly dose.

Bionano Genomics brings back OGM pioneer Dr. Alex Hastie as CSO. It's a strategic move to accelerate clinical adoption and restore investor confidence.

A new preclinical platform from HKeyBio aims to solve key bottlenecks in developing drugs for debilitating gut disorders. Is this the execution-focused approach the industry needs?

Calidi Biotherapeutics' RedTail platform uses a virus to make tumors produce their own medicine, a strategy that could finally defeat solid cancers.

Heparin, a trusted blood thinner, can trigger a fatal immune reaction. A small biotech's novel drug is now taking the global stage with a targeted solution.

Imbria's ninerafaxstat gains FDA Orphan Drug status for nHCM, a rare heart condition. This strategic win pits its unique metabolic approach against rivals.

Facing delisting, Virax Biolabs consolidates its shares in a bid to survive. This move buys time, but the real test lies in its innovative T-cell technology.

A strategic partnership between IMU Biosciences and Waters Corp. aims to pair AI with advanced hardware, creating a high-definition map of our immune system.

Despite passing all resolutions, Novavax faces a reckoning as nearly half of shareholders reject its pay plan, amplifying activist investor Shah Capital's demands.

A key FDA alignment for zervimesine not only de-risks a pivotal trial but signals a new era for treating the devastating psychosis of an overlooked dementia.

An alliance of biopharma innovators is set to discuss a critical hurdle in medicine: delivering RNA therapies to tissues beyond the liver, a key to unlocking new treatments.

With M&A veterans Martin Babler and Troy Cox joining its board, MapLight Therapeutics is signaling a strategic shift from foundational research to late-stage execution.

Ollin Biosciences secured $330M to challenge giants like Roche and Regeneron. Their next-gen antibody shows early promise in treating vision loss.

Novartis is betting nearly $2 billion on Antares Therapeutics' novel platform to conquer historically 'undruggable' cancer targets, a move that could redefine oncology.

A massive $115M funding round fuels UK biotech RQ Bio's quest to replace the annual flu shot for the vulnerable with a single, season-long antibody treatment.

After game-changing FDA news for its Huntington's therapy, uniQure's upsized $225M offering signals massive investor confidence and accelerates its mission.